Alnylam Pharmaceuticals delivered robust fourth quarter and full year 2024 financial results, although it slightly missed EPS expectations. With a revised price target of $300 from Scotiabank and buy rating retained by Needham & Company LLC, market analysts remain optimistic about the company's prospects. The potential of
Amvuttra, a drug for ATTR-CM, is considered a high growth opportunity for Alnylam. Notably, a series of positive results were reported on the earnings call. Forecasts for fiscal year 2025 project a strong revenue range between $2.05 billion and $2.25 billion. Significant interest from investment groups like Sumitomo Mitsui Trust, Savant Capital and Strategic Financial Concepts hints at promising trends. Alnylam has also submitted a regulatory application for
Vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy to the European Medicines Agency while the US FDA has accepted the Supplemental New Drug Application for the same. The strong sales, strategic developments, as well as the company's future profitability potential support the buy rating. Furthermore, Alnylam's expansion of its existing partnership with Medison Pharma is a crucial step towards commercializing RNAi therapeutics in LATAM and APAC markets. Biotech veteran John Maraganore's initiative to kick start a 'next-generation RNAi' startup, along with positive trial results of
nucresiran, further strengthen the company's innovative profile.
Alnylam Pharmaceuticals News Analytics from Tue, 30 Apr 2024 07:00:00 GMT to Sat, 15 Feb 2025 18:53:01 GMT -
Rating 7
- Innovation 8
- Information 9
- Rumor 2
